ReviewBiosensors2026
The Fragmented Nature of Biosensor Development: Challenges and Paths to Mitigation.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically encoded biosensors are now central tools, deployed either as intracellular reporters to advance basic research, or as whole-cell reagents that detect analytes in diverse sample-types. Across the diversity of molecular scaffolds and modes of operation, biosensors serve a common functional purpose: translating ligand presence into a readable signal. Despite this shared logic, biosensor development as a field of practice remains fragmented: different scaffolds and modalities are advanced in separate, often lab-specific pipelines with diverse assays, metrics, and design practices. Moreover, libraries, selection histories and performance data generated during routine campaigns rarely outlive the projects that produced them. In this perspective, we focus on this fragmentation as a field-level bottleneck and argue that it deserves explicit attention in its own right. We discuss how modest, incremental steps-such as structured development records, adherence to high-information screening formats, library annotation, and community-level deposition infrastructure-could make biosensor development more reproducible, more comparable, and easier to build on across projects and laboratories. We further argue that such infrastructure will become increasingly valuable as computational protein design matures-not as a competing approach, but as the source of diverse, comparable, and context-annotated experimental data that sequence-function models and design benchmarks ultimately depend on.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.